Dáil Éireann Debate, Wednesday - 28 September 2022
246. Deputy Josepha Madigan asked the Minister for Health the estimated cost of making continuous glucose monitors available on the long-term illness scheme for all those living with type 1 diabetes; and if he will make a statement on the matter. [47432/22]
View answerThe Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines and medical items, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. In making a relevant reimbursement decision, the HSE is required under the Act to have regard to a number of criteria including efficacy, the health needs of the public, cost effectiveness and potential or actual budget impact.
The HSE is unable to provide the cost of extending eligibility for a continuous glucose monitoring device to all people with type 1 diabetes, in the absence of a full Health Technology Assessment. The HSE has asked the Health Information and Quality Authority to undertake a system wide review which would include an assessment of budgetary impacts.
